

# Tuberculosis profile: Thailand

Population 2021: 72 million

## Estimates of TB burden\*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	103 000 (79 000-129 000)	143 (111-180)
HIV-positive TB incidence	8 900 (6 600-12 000)	12 (9.3-16)
MDR/RR-TB incidence**	2 400 (1 200-3 600)	3.4 (1.7-5.1)
HIV-negative TB mortality	9 600 (7 400-12 000)	13 (10-17)
HIV-positive TB mortality	1 700 (1 200-2 300)	2.4 (1.7-3.3)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2021

New cases	1.7% (1.1-2.6)
Previously treated cases	9.8% (9.2-11)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2021	70% (56-90)
TB patients facing catastrophic total costs, 2020	30% (26-34)
TB case fatality ratio (estimated mortality/estimated incidence), 2021	11% (8-15)

## TB case notifications, 2021

Total new and relapse	71 488
- % tested with rapid diagnostics at time of diagnosis	52%
- % with known HIV status	84%
- % pulmonary	85%
- % bacteriologically confirmed ^	69%
- % children aged 0-14 years	<1%
- % women (aged ≥15 years)	32%
- % men (aged ≥15 years)	68%
Total cases notified	72 851

## TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	5 313	8.8%
- on antiretroviral therapy	4 795	90%

## Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	76%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	90%
Laboratory-confirmed cases - MDR/RR-TB ^^	844
Patients started on treatment - MDR/RR-TB ^^	838
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	49
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	44
MDR/RR-TB cases tested for resistance to any fluoroquinolone	305

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	83%	85 837
Previously treated cases, excluding relapse, registered in 2020	64%	1 688
HIV-positive TB cases registered in 2020	74%	6 631
MDR/RR-TB cases started on second-line treatment in 2019	70%	1 095
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	82%	17


## TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)


## Funding for TB

Funding for TB, 2021 (US\$ millions)	26
- % domestic funding	78%
- % international funding	22%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2021 (Number)



## Cases attributable to five risk factors, 2021 (Number)



## Funding for TB (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
\*\* RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
^ Calculated for pulmonary cases only  
^^ Includes cases with unknown previous TB treatment history  
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

---

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)